Systemic side-effects of three topical steroids in diseased skin
- 1 January 1983
- journal article
- clinical trial
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 8 (7) , 475-480
- https://doi.org/10.1185/03007998309109785
Abstract
Two clinical trials were carried out in order to study adrenal suppression in 6 patients with psoriatic erythroderma and in 28 patients with psoriasis treated with topical glucocorticosteroids. Betamethasone-17-valerate (0.1%), betamethasone-17,21-dipropionate (0.05%) and budesonide (0.025%) ointments were studied in erythroderma; betamethasone-17,21-dipropionate and budesonide in psoriasis. The erythroderma study was an open, crossover experiment; the psoriasis study was a double-blind, group-comparative study. Adrenal suppression was measured as plasma cortisol concentrations with and without ACTH stimulation. The depressive activity on the HPA-axis in increasing order was budesonide, Detamethasone-17-valerate and betamethasone-17,21-dipropionate. The dxferences. however; did not reach statisticallq, significant levels.Keywords
This publication has 3 references indexed in Scilit:
- A double-blind trial of budesonide and betamethasone-17, 21-dipropionate in psoriasisCurrent Medical Research and Opinion, 1982
- A Double-Blind Trial of Budesonide Ointment and Betamethasone-17-Valerate Ointment in PsoriasisJournal of International Medical Research, 1981
- Complications of topical corticosteroid therapy in patients with liver diseaseBritish Journal of Dermatology, 1974